Home / Audit and Guideline / Link For Guideline / Coronavirus updates / Approval of GxP documents when working from home during the coronavirus (COVID-19) outbreak

Approval of GxP documents when working from home during the coronavirus (COVID-19) outbreak

Guidance for organisations involved in any aspect of the pharmaceutical lifecycle or GLP studies regulated by MHRA, covering the approval of paper documents when working from home

Published 9 April 2020
From: Medicines and Healthcare products Regulatory Agency
Contents
1. Existing electronic systems
2. Paper documents that were approved with wet ink signature
3. Alternative methods
4. Further information
Due to the COVID-19 pandemic, remote working has increased. Some organisations have advised that their processes for approving paper documents with wet ink signatures are no longer achievable.

This guidance is to enable organisations to consider alternative methods whilst maintaining basic control of
documents.
The guidance is for organisations involved in the pharmaceutical lifecycle (GMP, GDP, GLP, GCP & GPvP)
or GLP studies regulated by the MHRA.

Existing electronic systems

Many companies already have validated systems that support electronic signatures on systems that are available remotely. If a company has these systems in place, then they should continue to use them.

Paper documents that were approved with wet ink signature

These are documents that have traditionally been printed on paper, physically handed to each reviewer in an office
and approved using wet ink signatures.
Examples may include, but are not limited to:

  • Validation protocols and reports
  • Risk assessments
  • Technical reports
  • Quality management system documents that are paper based such as SOPs, investigations and change requests.

These can be shared with remote workers, but they have no formal system describing how the review and approval
can be recorded.

Alternative methods

The solution will vary between organisations depending on the type of document and the tools available to the person
performing the approval e.g. printer, scanner/smartphone,secure email, third party software or existing systems that
have tools to capture electronic signatures.

Principles to maintain control

Regardless of what system or process is used, the following principles apply:

  •  Controls should be proportionate to the risk considering the type of document and the methods used for distribution and approval.
  • A signature performed remotely should be equivalent to the handwritten signature of the signatory.
  • The method of document distribution and approval should be defined to minimise the risk of error due to misunderstanding of what is being reviewed/approved

Risks with remote approval

Aspects to consider when assessing risk include:

  • How the approval signature is attributable to an individual
  • Whether there is a legislative requirement or GxP guidance for a signature. If there is, then the signature should be considered more critical and have proportionately greater control – for example when a QP certifies a batch of finished product to enable release for sale.
  • The security of the electronic signature i.e. so that it can only be applied by the ‘owner’ of that signature.
  • How the act of ‘signing’ is recorded so that the document cannot be altered or manipulated without invalidating the signature or status of the entry.
  • Ensuring that all required associated data is available to a remote reviewer that would have been available to them if they were performing the review at a site.

Some examples of issues with remote approval are included in Examples of issues with remote approval (PDF, 305KB, 4 pages).
In these examples, had the distribution and approval process been clearly defined and assessed, it is unlikely that these issues would have occurred.

 

 

 

 

 

 

 

 

About Pharmaceutical Guidanace

Mr. Shiv Kumar is the Author and founder of pharmaceutical guidance, he is a pharmaceutical Professional from India having more than 14 years of rich experience in pharmaceutical field. During his career, he work in quality assurance department with multinational company’s i.e Zydus Cadila Ltd, Unichem Laboratories Ltd, Indoco remedies Ltd, Panacea Biotec Ltd, Nectar life Science Ltd. During his experience, he face may regulatory Audit i.e. USFDA, MHRA, ANVISA, MCC, TGA, EU –GMP, WHO –Geneva, ISO 9001-2008 and many ROW Regularities Audit i.e.Uganda,Kenya, Tanzania, Zimbabwe. He is currently leading a regulatory pharmaceutical company as a head Quality. You can join him by Email, Facebook, Google+, Twitter and YouTube

Check Also

SOP to prevent the spread of COVID 19 infection at workplace

1.0 OBJECTIVE: To lay down a Standard Operating Procedure to prevent the spread of COVID …